PHILADELPHIA, PA – A significant change to the U.S. advanced medical technology industry’s operating environment could cost tens of thousands of jobs, lower personal incomes and reduce business opportunities worldwide, according to a new study released today by the Advanced Medical Technology Association (AdvaMed).Continue reading
The Food and Drug Administration’s long-awaited guidelines for the sale of lower-cost versions of biotechnology drugs leave open the possibility that some products might not need to be tested in humans.Continue reading
Phoenix Analysis & Design Technologies, Inc. (PADT) and M-Tech Industrial (Pty) Ltd. announced the official launch of PADT as a distributor of the Flownex Simulation Environment in the Southwestern United States. The addition of Flownex to the products and services that PADT already offers broadens the range of solutions that the company can provide to its customers, specifically in the area of system modeling of fluid and thermal systems.Continue reading
October 20, 2011 , WASHINGTON, D.C.
Ann-Marie Lynch, executive vice president of the Advanced Medical Technology Association (AdvaMed), released the following statement regarding the Centers for Medicare and Medicaid Services (CMS) final rule on Accountable Care Organizations (ACOs):Continue reading
WASHINGTON,D.C. –The medical device tax, if implemented, could cost tens of thousands of jobs, almost double the industry’s total taxes, raise the effective tax rate to among the highest in the world, and harm U.S. competiveness, according to a study released today by the Advanced Medical Technology Association (AdvaMed). The new study, “Employment Effects of the New Excise Tax on the Medical Device Industry,” by Manhattan Institute senior fellow Diana Furchtgott-Roth and Hudson Institute senior fellow Harold Furchtgott-Roth, outlines a number of economic harms likely to result from the tax.Continue reading
AZBIO Washington Watch
Several minority organizations and disease advocacy groups are starting a website to track concerns about and opposition to the Independent Payment Advisory Board.Continue reading
WASHINGTON, D.C. (Wednesday, June 29, 2011) – The Biotechnology Industry Organization (BIO) released today a summary of legislative proposals to reform the investment and regulatory environment for biotech innovation. These proposals are designed to unleash the innovation required to cure disease and make the U.S. healthcare system more affordable, efficient, and of higher quality, as well as to foster the development of breakthrough technologies to provide alternative energy sources, combat hunger and protect against bio-terrorism. The policy proposals, released at a press briefing at the 2011 BIO International Convention held here this week, will serve as the organization’s targeted advocacy plan in these two areas.
There has been a lot of talk about budgets and debt ceilings in Washington this week. The negotiations – now taking place between the President and Congressional leaders are fluid, closely held, and difficult to predict. It does not take a PhD to know that Medicare and Medicaid cuts are on the table.